S&P 500   4,350.02 (+0.46%)
DOW   34,111.68 (+0.12%)
QQQ   360.77 (+0.81%)
AAPL   175.69 (+1.01%)
MSFT   320.05 (+0.16%)
META   304.90 (+3.10%)
GOOGL   131.78 (+1.03%)
AMZN   131.25 (+1.48%)
TSLA   254.40 (-0.51%)
NVDA   417.05 (+1.68%)
NIO   8.65 (+2.37%)
BABA   88.61 (+5.35%)
AMD   97.74 (+1.70%)
T   15.16 (-0.98%)
F   12.63 (+3.52%)
MU   69.22 (+1.94%)
CGC   0.85 (+10.14%)
GE   113.12 (+0.12%)
DIS   82.47 (-0.31%)
AMC   7.87 (+2.21%)
PFE   32.57 (-0.85%)
PYPL   58.97 (+0.60%)
NFLX   383.88 (-0.07%)
S&P 500   4,350.02 (+0.46%)
DOW   34,111.68 (+0.12%)
QQQ   360.77 (+0.81%)
AAPL   175.69 (+1.01%)
MSFT   320.05 (+0.16%)
META   304.90 (+3.10%)
GOOGL   131.78 (+1.03%)
AMZN   131.25 (+1.48%)
TSLA   254.40 (-0.51%)
NVDA   417.05 (+1.68%)
NIO   8.65 (+2.37%)
BABA   88.61 (+5.35%)
AMD   97.74 (+1.70%)
T   15.16 (-0.98%)
F   12.63 (+3.52%)
MU   69.22 (+1.94%)
CGC   0.85 (+10.14%)
GE   113.12 (+0.12%)
DIS   82.47 (-0.31%)
AMC   7.87 (+2.21%)
PFE   32.57 (-0.85%)
PYPL   58.97 (+0.60%)
NFLX   383.88 (-0.07%)
S&P 500   4,350.02 (+0.46%)
DOW   34,111.68 (+0.12%)
QQQ   360.77 (+0.81%)
AAPL   175.69 (+1.01%)
MSFT   320.05 (+0.16%)
META   304.90 (+3.10%)
GOOGL   131.78 (+1.03%)
AMZN   131.25 (+1.48%)
TSLA   254.40 (-0.51%)
NVDA   417.05 (+1.68%)
NIO   8.65 (+2.37%)
BABA   88.61 (+5.35%)
AMD   97.74 (+1.70%)
T   15.16 (-0.98%)
F   12.63 (+3.52%)
MU   69.22 (+1.94%)
CGC   0.85 (+10.14%)
GE   113.12 (+0.12%)
DIS   82.47 (-0.31%)
AMC   7.87 (+2.21%)
PFE   32.57 (-0.85%)
PYPL   58.97 (+0.60%)
NFLX   383.88 (-0.07%)
S&P 500   4,350.02 (+0.46%)
DOW   34,111.68 (+0.12%)
QQQ   360.77 (+0.81%)
AAPL   175.69 (+1.01%)
MSFT   320.05 (+0.16%)
META   304.90 (+3.10%)
GOOGL   131.78 (+1.03%)
AMZN   131.25 (+1.48%)
TSLA   254.40 (-0.51%)
NVDA   417.05 (+1.68%)
NIO   8.65 (+2.37%)
BABA   88.61 (+5.35%)
AMD   97.74 (+1.70%)
T   15.16 (-0.98%)
F   12.63 (+3.52%)
MU   69.22 (+1.94%)
CGC   0.85 (+10.14%)
GE   113.12 (+0.12%)
DIS   82.47 (-0.31%)
AMC   7.87 (+2.21%)
PFE   32.57 (-0.85%)
PYPL   58.97 (+0.60%)
NFLX   383.88 (-0.07%)
NASDAQ:ALVR

AlloVir (ALVR) Stock Forecast, Price & News

$2.22
-0.05 (-2.20%)
(As of 10:33 AM ET)
Compare
Today's Range
$2.18
$2.28
50-Day Range
$2.15
$3.64
52-Week Range
$1.90
$10.29
Volume
138,690 shs
Average Volume
527,571 shs
Market Capitalization
$252.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.75

AlloVir MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
726.0% Upside
$18.75 Price Target
Short Interest
Bearish
7.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of AlloVir in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$10.99 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.73) to ($1.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

253rd out of 965 stocks

Biological Products, Except Diagnostic Industry

33rd out of 162 stocks


ALVR stock logo

About AlloVir (NASDAQ:ALVR) Stock

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

ALVR Price History

ALVR Stock News Headlines

Why AlloVir Stock Dropped Today
AlloVir, Inc. (NASDAQ:ALVR) Sees Large Growth in Short Interest
Save $300 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $300 account credit and free 30-day trial subscription today.
AlloVir (NASDAQ:ALVR) Shares Down 1.7%
AlloVir to Present at Upcoming Investor Conferences
Save $300 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $300 account credit and free 30-day trial subscription today.
Bank of America Securities Initiates a Buy Rating on AlloVir (ALVR)
AlloVir Reports Second Quarter 2023 Financial Results
AlloVir: 'Takes One To Know One'
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why
Why Shares of AlloVir Plummeted This Week
AlloVir Prices Public Offering
Why AlloVir Stock Is Diving Thursday
Why Is AlloVir (ALVR) Stock Down 23% Today?
Pre-market Movers: PIXY, ROOT, CDMO, ALVR, KWE…
AlloVir Tanks after Stock Offering
AlloVir plans for $75M stock offering
See More Headlines
Receive ALVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter.

ALVR Company Calendar

Last Earnings
8/03/2023
Today
9/22/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALVR
Fax
N/A
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.75
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+726.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-168,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.41 per share

Miscellaneous

Free Float
68,356,000
Market Cap
$258.48 million
Optionable
Not Optionable
Beta
0.65
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. David L. HallalMr. David L. Hallal (Age 57)
    Exec. Chairman
    Comp: $254.38k
  • Dr. Diana M. Brainard M.D. (Age 52)
    CEO & Director
    Comp: $978.99k
  • Mr. Vikas Sinha C.A. (Age 60)
    CPA, M.B.A., Pres, CFO & Director
    Comp: $536.21k
  • Mr. Edward Miller J.D. (Age 58)
    Gen. Counsel & Sec.
    Comp: $618.39k
  • Mr. Brett R. HagenMr. Brett R. Hagen (Age 50)
    Chief Accounting Officer
  • Mr. Dana M. Alexander (Age 47)
    Sr. VP of Technical Operations
  • Dr. Ann M. Leen Ph.D. (Age 46)
    Chief Scientific Officer
  • Ms. Sonia Choi
    Sr. VP of Corp. Affairs & Investor Relations
  • Mr. Ugo Capolino Perlingieri
    Head & GM of Europe and Middle East Operations
  • Ms. Cintia Piccina Pharm.D. (Age 50)
    Chief Commercial Officer













ALVR Stock - Frequently Asked Questions

Should I buy or sell AlloVir stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALVR shares.
View ALVR analyst ratings
or view top-rated stocks.

What is AlloVir's stock price forecast for 2023?

3 brokers have issued twelve-month price targets for AlloVir's shares. Their ALVR share price forecasts range from $17.00 to $20.00. On average, they anticipate the company's share price to reach $18.75 in the next twelve months. This suggests a possible upside of 726.0% from the stock's current price.
View analysts price targets for ALVR
or view top-rated stocks among Wall Street analysts.

How have ALVR shares performed in 2023?

AlloVir's stock was trading at $5.13 at the beginning of the year. Since then, ALVR stock has decreased by 55.8% and is now trading at $2.27.
View the best growth stocks for 2023 here
.

Are investors shorting AlloVir?

AlloVir saw a increase in short interest in August. As of August 31st, there was short interest totaling 8,310,000 shares, an increase of 7.6% from the August 15th total of 7,720,000 shares. Based on an average daily trading volume, of 868,900 shares, the days-to-cover ratio is presently 9.6 days.
View AlloVir's Short Interest
.

When is AlloVir's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ALVR earnings forecast
.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.03.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).

When did AlloVir IPO?

(ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is AlloVir's stock symbol?

AlloVir trades on the NASDAQ under the ticker symbol "ALVR."

Who are AlloVir's major shareholders?

AlloVir's stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (5.84%), Artal Group S.A. (5.79%), BlackRock Inc. (2.92%), Woodline Partners LP (1.52%), American International Group Inc. (1.01%) and JPMorgan Chase & Co. (0.96%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha.
View institutional ownership trends
.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AlloVir's stock price today?

One share of ALVR stock can currently be purchased for approximately $2.27.

How much money does AlloVir make?

AlloVir (NASDAQ:ALVR) has a market capitalization of $258.48 million. The company earns $-168,710,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

How many employees does AlloVir have?

The company employs 113 workers across the globe.

How can I contact AlloVir?

AlloVir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The official website for the company is www.allovir.com. The company can be reached via phone at 617-433-2605 or via email at ir@allovir.com.

This page (NASDAQ:ALVR) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -